Study design
toxicity, head and neck carcinoma
DISEASE PROGRESSION, METASTATIC RENAL CELL CARCINOMA, METASTATIC BLADDER CANCER, OTHER CANCER, METASTATIC NON-SMALL CELL LUNG CANCER
This trial will include two parts:The first part will be a monocentric, open-label, phase I, with the aim of establishing the recommended safety scheme of administration (concomitant or sequential) of tiragolumab + atezolizumab + SBRT. Only patients suffering from metastatic non-small cell lung cancer (cohort 1) will be enrolled in phase I. Other cancers will be studied in the second part of the study.The second part will be a multicentric study, open-label, expansion cohorts phase under the recommended scheme of administration. Patients from 4 different cohorts (metastatic non-small cell lung cancer, metastatic bladder cancer, metastatic renal cell carcinoma, and metastatic head and neck carcinoma) will be enrolled in the second part.Patients will be treated until disease progression, unacceptable toxicity, intercurrent conditions that preclude continuation of treatment, or patient refusal in the absence of progression or intolerance. The maximum duration of the treatment with immunotherapy will be 24 months.